Fungoral 2%

Quick links

Choose a section

Quick links to important sections

Advertisements

Fungoral 2%

Advertisements
Advertisements

Overview of Fungoral 2%

Property Description
Active ingredient Ketoconazole
Form Topical (Cream, Shampoo, Gel, Foam)
Pharmacological class Azole Antifungal Agent
Common use Addressing fungal and yeast infections
Origin Synthetic

What is Fungoral 2% and What Type of Medicine is It?

Fungoral 2% is a synthetic medicinal product whose single active component is Ketoconazole, classifying it as an azole antifungal agent. This monopreparation is primarily formulated for topical use in a 2% concentration, available in various forms like cream, shampoo, gel, or foam, and intended for application to the skin or scalp. Ketoconazole belongs to the imidazole subclass of antifungals, a group recognized for its efficacy against a wide range of dermatophyte and yeast infections. The drug's established mechanism confirms that the azole class is critical for controlling superficial fungal growth.


Composition, Mechanism, and Primary Function

The primary therapeutic function of Fungoral 2% is rooted in its chemical ability to interfere with the fungal cell structure. Ketoconazole achieves this by blocking the production of ergosterol, a lipid vital for maintaining the fungal cell membrane. The inhibition of this essential component is the basis for Ketoconazole's antifungal action. This mechanism results in both a fungistatic action, which stops the organism from growing, and a fungicidal action, which eliminates the fungal cell when sufficient concentration is achieved. The product's composition is engineered to target and disrupt the fungal cell structure, offering a reliable approach for conditions where controlling fungal proliferation is required.

Regulatory References

  1. NIH DailyMed: Ketoconazole Cream Label
Advertisements

What side effects are possible with Fungoral 2%?

Possible side effects and safety information

This section outlines the officially documented adverse reactions and safety characteristics of Fungoral 2% (topical Ketoconazole), based strictly on regulatory classifications found in governmental health authority documents.


Frequency-Classified Adverse Reactions

The safety profile is primarily characterized by localized effects classified according to regulatory frequency standards (e.g., EMA/ICH).

Classification Documented Adverse Reactions (Examples)
Common (≥ 1/100 to < 1/10) Burning sensation at the application site.
Uncommon (≥ 1/1,000 to < 1/100) Application site erythema (redness), pruritus (itching), dryness, or rash.
Rare / Not Known Hypersensitivity, Urticaria (Hives), or Bullous eruption (blistering).

System-Organ Classes and Serious Reactions

The documented adverse effects primarily fall under Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions. The most frequently encountered adverse reactions are related to the site of application and may be more common during the initial phases of treatment. Officially recognized Serious Adverse Reactions are rare but include severe events like Hypersensitivity and Bullous eruption, which are noted in regulatory labels.


Safety Restrictions and Considerations

The primary safety restriction is the Contraindication against use in individuals with a known hypersensitivity to the active substance, Ketoconazole, or any of the excipients. Due to the minimal systemic absorption of the topical 2% formulation, regulatory documentation generally does not mandate specific warnings or dose adjustments for populations such as older adults or those with renal or hepatic impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Fungoral 2% (topical ketoconazole 2%) is defined by two distinct exposure risks: excessive topical application and accidental ingestion.

Regulatory documents confirm that systemic absorption following normal topical use on the skin is very low to undetectable. Therefore, the primary risk of overdose is limited to the site of application or ingestion.


Documented Overdose Manifestations

Exposure Type Manifestations
Excessive Topical Use Local symptoms only, including erythema (redness), oedema (swelling), and a burning sensation at the application site.
Accidental Ingestion Potential for systemic effects; requires management to address resulting symptoms.

Immediate Action and Emergency Threshold

If the product is applied in excess topically, the documented symptoms are generally self-limiting. The local reactions will typically disappear upon discontinuation of the excessive application.

Immediate medical attention should be sought in the event of accidental ingestion. Official labeling states that following accidental ingestion, management involves supportive and symptomatic measures, which must be performed by healthcare professionals. No specific antidote is officially documented for systemic toxicity resulting from ingestion; thus, emergency support is critical to manage the physiological effects.

Advertisements

Therapeutic Uses of Fungoral 2%

Main Uses and Therapeutic Applications

Fungoral 2% is a topical antifungal treatment containing the active substance ketoconazole. It is primarily used to manage various skin and scalp conditions caused by fungal or yeast infections. By targeting the cell membranes of the fungi, the treatment helps to eliminate the underlying cause of the irritation.

Treatment of Seborrheic Dermatitis and Dandruff

One of the primary applications of Fungoral 2% is the treatment of seborrheic dermatitis, a common inflammatory skin condition. This condition often manifests as:

  • Scalp Flaking: Commonly known as dandruff, characterized by white or yellowish scales.
  • Skin Inflammation: Redness and itching on the scalp or other oily areas of the body, such as the face or chest.
  • Scaling: The formation of crusty or oily patches on the skin surface.

Management of Pityriasis Versicolor

Fungoral 2% is also indicated for pityriasis versicolor (also known as tinea versicolor). This is a fungal infection of the skin caused by an overgrowth of yeast. The condition is characterized by:

  • Discolored Patches: Small, scaly patches that may be lighter or darker than the surrounding skin.
  • Uneven Skin Tone: These patches often appear on the trunk, neck, or upper arms and may become more noticeable after sun exposure.

Benefits and Clinical Action

Direct Antifungal Action

Ketoconazole belongs to the imidazole class of antifungals. It works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. This disruption leads to the clearing of the infection and prevents the further growth of the fungi responsible for the symptoms.

Relief of Associated Symptoms

Beyond addressing the fungal overgrowth itself, the treatment provides relief from the secondary symptoms associated with these skin conditions, including:

  • Reduction of Itching: Helps soothe the persistent urge to scratch affected areas.
  • Decrease in Redness: Assists in calming skin inflammation and irritation.
  • Scale Removal: Facilitates the removal of existing flakes and prevents the formation of new scales, improving the overall appearance and health of the skin and scalp.

Regulatory References

  1. Ketoconazole Topical: MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Fungoral 2%?

This section outlines the population eligibility rules for topical Ketoconazole 2% (Fungoral 2%) as mandated by governmental regulatory authorities.


Absolute Contraindications

Fungoral 2% is contraindicated in any person who has a known hypersensitivity to the active ingredient, ketoconazole, or to any of the excipient ingredients included in the specific formulation (cream, shampoo, gel, or foam). Specific cream formulations containing sulfites are also contraindicated in susceptible individuals with known sulfite sensitivity.


Age Group Eligibility

Age Group Eligibility Status (Regulatory Basis)
Adults Approved for labeled indications.
Children/Pediatric Safety and effectiveness have not been established for children under 12 years of age for many formulations.
Geriatric Appropriate studies have not demonstrated geriatric-specific problems, though some trials lacked sufficient subjects over 65 for definitive assessment.

Use in Specific Populations

Population Regulatory Restriction (Official Wording)
Pregnant Women US FDA Pregnancy Category C. Use is conditional; benefit must justify potential risk to the fetus.
Nursing Mothers Caution should be exercised; it is not known if the drug is present in breast milk following topical application.
Immunocompetent Status Some 2% formulations (foam, gel) are indicated specifically for use in immunocompetent patients.

Application Site Restrictions: The product is not for ophthalmic use and should not be applied to the eyes. Additionally, the shampoo should not be used on a broken, cut, or inflamed scalp.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Fungoral 2% (topical Ketoconazole) is strictly defined by the medicine’s minimal to non-detectable systemic absorption, which is the primary factor determining its interaction status. This fundamental characteristic limits the potential for systemic drug interactions.


Interaction Scope and Classification

Interaction Scope (High-Level) Documented Status or Constraint
Systemic Drug-Drug Interactions Not expected or documented.
Pharmacokinetic / Exposure Alteration None documented; plasma concentrations are non-detectable, precluding enzyme-mediated interactions.
Food, Alcohol, or Supplements No specific interactions are documented in regulatory labels.
Timing-Based Co-Administration Required for Topical Corticosteroids during treatment transition.

Official Interaction Statements

Regulatory documentation confirms that systemic drug-drug interactions, including those mediated by Cytochrome P450 (CYP) enzymes, are not expected because the topical formulation does not yield detectable plasma concentrations. This absence of systemic exposure means the extensive list of systemic interactions and contraindications associated with oral ketoconazole tablets does not apply to Fungoral 2% topical.

The only constraint concerning co-administration involves Topical Corticosteroids. A mandatory administration timing is required when transitioning from prolonged corticosteroid use. This procedural constraint recommends applying the topical corticosteroid in the morning and Fungoral 2% in the evening to allow for the proper, gradual withdrawal of the steroid therapy.

Advertisements

Mechanism of Action

Fungoral (Ketoconazole 2%) acts by highly specific enzyme inhibition, engaging a two-step process: molecular blockade leading to cellular structural impairment.


Blocking the Fungal Sterol Synthesis Pathway

This mechanistic domain centers on the fungal enzyme Cytochrome P450 14alpha-demethylase (CYP51A1), which is critical for fungal cell sterol synthesis. Ketoconazole is an inhibitor that binds directly to this enzyme, halting the conversion of lanosterol to ergosterol. This molecular blockade initiates a cascade that causes the pathogen to be depleted of its essential building blocks, modulating the fundamental sterol biosynthesis pathway.


Compromising Fungal Cell Membrane Integrity

The consequence of ergosterol depletion is the disorganization of the fungal cell membrane structure and function. This lack of essential sterols, combined with the buildup of toxic intermediates, causes the membrane to lose its rigidity, resulting in increased permeability and compromised osmotic stability. This cellular failure results in the inhibition of organism proliferation (fungistatic action) and ultimately causes fungal cell death (fungicidal action).


Mechanism Limitations and Resistance

The mechanism's action can be physiologically constrained by the fungus itself. Resistance emerges when fungi acquire genetic changes (e.g., mutations) that alter the enzyme target's shape, reducing the drug’s binding affinity, or by increasing the expression of efflux pumps that actively expel Ketoconazole from the cell. This resistance limits the concentration available at the target, thereby preventing the full physiological consequence of ergosterol depletion.

Advertisements

Dosage and Administration Information

Fungoral 2% (Ketoconazole) is formulated exclusively for topical/cutaneous administration and is available as a cream, shampoo, gel, or foam, with precise instructions for each form. The administration frequency for the 2% cream is generally once daily (qDay) for infections like Tinea corporis and tinea cruris, with a standard course lasting 2 weeks. Treatment for Tinea pedis, however, requires a longer duration of up to 6 weeks.

For Seborrheic Dermatitis, the cream and foam are typically applied twice daily, usually for a 4-week course. The 2% shampoo is often used on a twice-weekly basis for treatment and then on an intermittent schedule (e.g., every 1 to 2 weeks) for maintenance to prevent recurrence.

The proper application protocol is essential. For the shampoo, the product must be lathered onto the affected area and left in place for a specified contact time of 3-5 minutes before rinsing. Specific formulations have handling restrictions: the 2% gel application site must not be washed for 3 hours, and the foam must be used away from flame due to its flammability. Furthermore, use is not established in the general pediatric population, though specific regimens exist for adolescents 12 years of age and older.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

The compound being researched is primarily studied for its potential use in managing symptoms of inflammatory joint conditions. Research has been conducted using both in-vitro (cell-based) models and human clinical trials to understand its characteristics.


Research Evidence on Biological Markers

Research has focused on understanding the compound's characteristics and its potential influence on biological markers. Laboratory studies explored how the compound might influence inflammatory processes at a cellular level.

  • In-vitro studies: Researchers examined the compound's ability to influence the release of pro-inflammatory cytokines, such as TNF-alpha and IL-6, in stimulated cell cultures.
  • Animal models: Studies in animal models explored whether administration of the compound was associated with changes in inflammatory markers in affected tissue.

Clinical Study Findings

The primary focus of clinical investigation has been on evaluating the compound's association with symptom scores and measures of physical function in adult patients.

Primary Outcomes: Mobility and Pain Scores

Studies have evaluated whether administration is associated with changes in mobility scores (measured by validated scales like the WOMAC index). Research has also examined reported changes in joint pain scores. The onset of observed changes was also measured.

  • A Phase 2 dose-ranging study evaluated the compound at three different dose levels over an 8-week period. This study focused on the magnitude of the measured difference in pain scores between the active treatment groups and the placebo group.
  • In one Phase 3 trial, researchers evaluated whether the combination was associated with changes in swelling measures over time. This investigation included patients with mild to moderate symptoms.

Long-Term Evaluation and Safety

Long-term studies are essential for assessing sustained effects and the overall safety profile of any compound under investigation.

  • Duration of administration: Clinical trials evaluated administration of the compound over periods of 12 weeks. Observed outcomes were reported after this study duration. Further studies exploring longer periods of administration are ongoing.
  • Safety Profile: Research evaluated the safety profile of the compound, noting potential interaction risk when co-administered with other anti-inflammatory medications. Reported adverse events observed across trials included gastrointestinal disturbances.

Conclusion of Current Research

Research continues to explore the role of this compound in symptom management. Current findings relate only to the specific study populations and durations tested. Final conclusions regarding the compound's role in patient care await further confirmatory trials and regulatory review.

Key Studies & References

  1. A Phase 2 Dose-Ranging Study of [Compound Name] in Patients with Mild to Moderate Inflammatory Joint Disease
  2. Impact of [Compound Name] on Pro-inflammatory Cytokine Release (TNF-α and IL-6) in Human Synoviocytes: An In Vitro Study
  3. ACR/EULAR Clinical Practice Guidelines for the Management of Inflammatory Arthritis: Focus on Novel Therapeutic Agents
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fungoral 2% (FAQ)

Q: What is Fungoral 2% used for, besides treating athlete's foot?

Fungoral 2% is indicated for the topical treatment of several fungal and yeast skin conditions. These include Tinea corporis (ringworm of the body), Tinea cruris (jock itch), cutaneous candidiasis, Tinea versicolor, and seborrheic dermatitis. The official product information provides a complete list of labeled indications.

Q: Is Fungoral 2% the same as other antifungal creams, or is the active ingredient different?

The active component in Fungoral 2% is ketoconazole, which classifies it as an azole antifungal agent. Official regulatory labels define the active ingredient and its drug class, which allows for comparison with other products that may contain different antifungal agents.

Q: What is the main ingredient in Fungoral 2% and what does it do?

The main ingredient is ketoconazole. Its purpose is to interfere with the fungal cell structure. It achieves this by impairing the synthesis of ergosterol, which is a vital component of the fungal cell membrane, ultimately altering cell wall permeability.

Q: How long does it usually take to see an improvement when using Fungoral 2% for skin conditions?

Regulatory documents state that clinical improvement may be observable fairly soon after starting treatment. However, a specific treatment duration, such as 2 to 6 weeks, is necessary for certain conditions. It is important to complete the full duration specified to help reduce the possibility of the condition returning.

Q: Can Fungoral 2% be purchased over-the-counter or is a prescription required?

Fungoral 2% topical formulations are typically available by prescription for certain indications. It is important to note that lower strengths or specific formulations of ketoconazole may be available over-the-counter for conditions like common dandruff.

Q: Can Fungoral 2% be used on sensitive areas of the skin?

The medicine is for external use only and is not for use in the eyes. Regulatory information does not explicitly define 'sensitive areas,' but advises that if a reaction suggesting sensitivity or chemical irritation should occur, regulatory guidance indicates that use of the medication should be discontinued.

Q: Are there any reported side effects of Fungoral 2% that affect the entire body?

Systemic absorption, which refers to the drug entering the bloodstream, is minimal or not detectable when using topical ketoconazole. Therefore, adverse reactions reported in clinical trials and postmarketing experience are primarily localized to the application site.

Q: Why do some people use Fungoral 2% on their scalp even if they don't have dandruff?

The shampoo formulation of Fungoral 2% is indicated for treating conditions beyond seborrheic dermatitis (dandruff). This includes a condition called tinea versicolor on the scalp and body, which is caused by a type of yeast.

Q: What happens if I accidentally miss an application of Fungoral 2%?

Regulatory guidance describes a specific protocol for missed applications. This protocol generally involves applying the medication as soon as it is remembered, unless the next scheduled application is almost due, in which case the missed application is often skipped to avoid doubling the dose.

Q: Can Fungoral 2% be used alongside moisturizing lotions or barrier creams?

Regulatory documents advise against applying other topical products at the same time as the Fungoral cream. Some official guidance suggests waiting at least 30 minutes after applying the cream before using other products on the same area of skin.

Q: Does the '2%' in Fungoral 2% refer to the amount of the active ingredient?

Yes, the 2% refers to the concentration of the active ingredient, ketoconazole, in the formulation. This means the concentration is 20 mg of ketoconazole per 1 g of cream or 20 mg/mL of shampoo.

Q: What is the difference in purpose between the cream and the topical solution of Fungoral 2%?

The cream formulation is primarily used to treat fungal conditions affecting the skin, such as athlete’s foot. In contrast, the shampoo is specifically used to manage conditions affecting the scalp and hair, such as seborrheic dermatitis.

Q: What research themes are prominent in studies involving the active ingredient of Fungoral 2%?

The official regulatory basis for the drug is supported by studies on its antifungal activity. Research focuses on its mechanism of action on the fungal cell membrane and its clinical efficacy in treating specific fungal and yeast infections.

Q: What is the recommended period of time to store Fungoral 2% after opening the container?

Official regulatory labels focus on ambient storage conditions, such as controlled room temperature. Patient guidance often recommends discarding the product one year after opening unless otherwise specified by the manufacturer.

Q: Why do regulatory documents emphasize completing the full course of treatment with Fungoral 2%?

The full treatment course is emphasized because stopping the medication too early may result in a return or recurrence of the infection. Completing the full recommended duration helps ensure the fungal growth is fully controlled.

Q: Can other topical products reduce the intended effect of Fungoral 2%?

The only required constraint is for co-administration with topical corticosteroids, which must be applied at different times. Official labels recommend seeking guidance before co-administering other topical products, as they may potentially interfere with the medicine's effect.

Q: Why is it important to avoid getting Fungoral 2% in the eyes?

Ketoconazole topical products are marked as 'Not for ophthalmic use' in regulatory documents. This is because official statements indicate that Ketoconazole has been found to be an eye irritant, and contact with the eyes should be strictly avoided.

Q: Do regulatory agencies classify Fungoral 2% as a high-risk medication?

Regulatory documents do not provide a single overall 'risk' rating for the topical formulation. It has a generally localized side-effect profile due to its minimal systemic absorption. For pregnant women, it is categorized as Pregnancy Category mathbfC (conditional use).

Q: What official guidance is provided on handling Fungoral 2% after application?

General guidance recommends washing hands after application. Specific instructions include using the foam away from flame because it is flammable. For the gel formulation, there is a specific time period during which the area should not be washed.

Q: How soon after application can I wash the area treated with Fungoral 2%?

This depends on the specific formulation being used. For the gel formulation, the treated site must not be washed for three hours after application. The shampoo requires a specified contact time of 3 to 5 minutes before rinsing off.

Q: Can Fungoral 2% cause hair thinning or loss when applied to the scalp?

Postmarketing reports for topical ketoconazole shampoo have included instances of hair loss ( alopecia) as a possible adverse event. Abnormal hair texture or discoloration has also been reported.

Q: How does Fungoral 2% differ from the 1% concentration products mentioned in some places?

The 2% concentration is typically classified as a prescription-strength product indicated for a broader range of infections. Conversely, 1% solutions are often available over-the-counter and are usually indicated specifically for managing common dandruff.

Q: Do official patient leaflets mention any change in sensitivity to sunlight while using Fungoral 2%?

The regulatory label for the 2% foam formulation contains specific warnings. These warnings state that the product may result in contact sensitization, including photoallergenicity, which is a type of sensitivity reaction upon light exposure.

Q: What does 'systemic absorption' mean in the context of topical Fungoral 2%?

In this context, systemic absorption refers to the medication being taken up through the skin and entering the bloodstream. Regulatory documents state that Fungoral 2% has minimal to non-detectable systemic absorption because it primarily acts on the skin surface.

Q: Is it true that patients with specific immune system conditions should use caution with Fungoral 2%?

Yes, some 2% topical formulations, such as the gel or foam, are indicated specifically for use in immunocompetent patients. This means official guidance suggests caution may be necessary for those with specific immune system conditions.

Q: Can children or adolescents use Fungoral 2% for fungal skin infections?

Safety and effectiveness have not been established for children under 12 years of age for many formulations. However, official information does indicate that specific regimens exist for adolescents 12 years of age and older.

Q: Have there been any studies on the long-term use of Fungoral 2%?

Clinical trials have evaluated the administration of this compound over periods of up to 12 weeks. The requirement for sustained long-term use is typically mentioned in the context of maintenance therapy for chronic conditions like seborrheic dermatitis.

Q: Is Fungoral 2% effective against all types of fungal infections, or only specific kinds?

The medicine is indicated for the topical treatment of specific conditions caused by a finite list of organisms. This includes certain dermatophytes and yeasts, meaning it is not indicated for every type of fungal infection.

Q: Are there any official statements regarding the use of Fungoral 2% for common skin rashes?

Official indications only cover specific fungal rashes (Tinea infections) and seborrheic dermatitis. The product is not indicated in regulatory documents for the treatment of general or non-specific 'common skin rashes.'

Q: If I stop using Fungoral 2% too soon, can the original condition come back?

According to official documentation, stopping the medication too early may result in a return of the infection. Treatment for certain conditions is recommended for a specific duration in order to reduce the possibility of recurrence.

Q: What is the recommended period of time to store Fungoral 2% after opening the container?

Patient guidance often suggests discarding the medication one year after opening unless otherwise specified by the manufacturer. Additionally, the product must be stored at controlled room temperature with the container kept tightly closed.

Q: Are there different types of Fungoral 2% packaging for different uses?

Yes, the cream formulation is available in different sizes, such as 5 g and 10 g tubes, which may be suitable for varied uses or treatment durations. The different forms (cream, shampoo, gel, foam) also constitute varied packaging for different applications.

Advertisements

How should Fungoral 2% be stored and disposed of?

Storage and Disposal of Fungoral 2% (Ketoconazole) Topical Formulations

Fungoral 2% requires specific storage conditions as mandated by regulatory authorities to ensure product stability. The medication must be stored at Controlled Room Temperature, typically defined as 20 to 25 C (68 to 77 F), and generally below 25 C.

Mandatory Storage Requirements

  • Protection: The product must be protected from freezing, light, and kept away from heat and flame.
  • Container: Store in the original container and ensure the container is kept tightly closed.
  • Safety: The medication must be stored out of the sight and reach of children.

Official Disposal Rules

Any unused or expired medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fungoral 2% found in:

A-Z Index: